From chemotherapy to targeted treatment

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Dummer, R ^a   Rozati, S ^a   Eggmann, N ^a   Rinderknecht, J ^a   Goldinger, S M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Biochemotherapy; Chemotherapy; Kinase inhibitor; Melanoma; Metastatic melanoma; Targeted therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DABRAFENIB; DACARBAZINE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PACLITAXEL; SELUMETINIB; TEMOZOLOMIDE; TRAMETINIB; VEMURAFENIB; VINBLASTINE; VINDESINE;

ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG PENETRATION; DRUG RESPONSE; EXON; FATIGUE; GENE FREQUENCY; GENE MUTATION; HUMAN; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; ONCOGENE; OVERALL SURVIVAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; V KIT HARDY ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG GENE; V RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1 GENE;

DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84866773136     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds308     Document Type: Article

References (26)

1. Eigentler TK, Caroli UM, Radny P et al. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003; 4(12): 748-759.
2. Patel PM, Suciu S, Mortier L et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 2011; 47(10): 1476-1483.
3. Hauschild A, Agarwala SS, Trefzer U et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009; 27(17): 2823-2830.
4. Hamm C, Verma S, Petrella T et al. Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. Cancer Treat Rev 2008; 34(2): 145-156.
5. Ives NJ, Stowe RL, Lorigan P et al. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007; 25(34): 5426-5434.
6. Omholt K, Grafstrom E, Kanter-Lewensohn L et al. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res 2011; 17(12): 3933-3942.
7. Schoenewolf NL, Bull C, Belloni B et al. Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. Eur J Cancer 2012; 48(12): 1842-1852.
8. Van Raamsdonk CD, Bezrookove V, Geen G et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457(7229): 599-602.
9. Van Raamsdonk CD, Griewank KG, Crosby MB et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363(23): 2191-2199.
10. Bollag G, Hirth P, Tsai J et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467(7315): 596-599.
11. Kefford RA, Arkenaua H, Brown MP et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010; 28(Suppl): Abstract 8503.
12. Long GV, Kefford RF, Carr PJ et al. Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (mut) BRAF kinase: evidence of activity in melanoma brain metastases (mets). Ann Oncol 2010; 21(Suppl 8): viii12.
13. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363(9): 809-819.
14. Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012; 366(5): 480-481.
15. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364(26): 2507-2516.
16. Oberholzer PA, Kee D, Dziunycz P et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30(3): 316-321.
17. Su F, Viros A, Milagre C et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366(3): 207-215.
18. Zimmer L, Hillen U, Livingstone E et al. Atypical melanocytic proliferations and new primary melanomas in advanced melanoma patients undergoing selective BRAF inhibition. J Clin Oncol 2012; 30(19): 2375-2383.
19. Pratilas CA, Taylor BS, Ye Q et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 2009; 106(11): 4519-4524.
20. Kirkwood JM, Bastholt L, Robert C et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012; 18(2): 555-567.
21. Infante JR, Fecher LA, Nallapareddy S et al. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. J Clin Oncol 2010; 28(Suppl): Abstract 2503.
22. Hodi FS, Friedlander P, Corless CL et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008; 26(12): 2046-2051.
23. Curtin JA, Busam K, Pinkel D et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24(26): 4340-4346.
24. Carvajal RD, Antonescu CR, Wolchok JD et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305(22): 2327-2334.
25. Guo J, Si L, Kong Y et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29(21): 2904-2909.
26. Dummer R, Flaherty KT. Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr Opin Oncol 2012; 24(2): 150-154.